Skip to main content

Pegradicase+immTOR SEL-212 Shows Promising Results in Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.

ACR 2019 - Report from Day One (Sunday)

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

A Focus on WOCBA (Women of Childbearing Age)

Many rheumatic diseases affect women of childbearing age. In the age of biologic therapy, women are achieving better disease activity and there are increasing numbers of women with rheumatic diseases attempting pregnancy. 

ACR 2018 - Day 4 Report

Highlights from Tuesday and Wednesday day 3  and 4 of the ACR Annual meeting in Chicago, included:

Rheumatology Roundup - Drs. Artie Kavanaugh and Jack Cush

Tweets

Dr. Antoni Chan synovialjoints

8 months ago

Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and abstract #2729 is promising as treatment options for patients #ACR19 @RheumNow

Dr. Antoni Chan synovialjoints

8 months ago

The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected safety findings. IXE superior to PBO for improving signs, symptoms, and inflammation on MRI in pts with nr-axSpA abstract #2729 #ACR19 @RheumNow

Dr. Antoni Chan synovialjoints

8 months ago

PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs and symptoms of nr-axSpA through Wk 16. The safety profile of SEC was consistent with the established safety profile across indications #L2 #ACR19 @RheumNow

Janet Pope Janetbirdope

8 months ago

Tofacitinib works in Polyarticular JIA. Maybe new hope for kids with JIA and benefits of oral medication #ACR #ACR19 #JIA @RheumNow L23.

Janet Pope Janetbirdope

8 months ago

1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how they get reimbursement #ACR #ACR19 #psoriaticarthritis @RheumNow abstract 1481

Janet Pope Janetbirdope

8 months ago

Remission ever or sustained in RA is same on triple DMARDs Therapy bs biological Rx. From Swedish register. ?channeling bias ?differential access? Either way this supports triple therapy use as impt in RA #ACR #ACR19 @RheumNow Abstract 2908 https://t.co/T8fRPr5a2A

Dr. Rachel Tate uptoTate

8 months ago

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M

Dr. Rachel Tate uptoTate

8 months ago

Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd #ACR19 @RheumNow abs#2877

Cassandra Calabrese CCalabreseDO

8 months ago

Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped at time of positive pregnancy test @RheumNow #ACR19

Janet Pope Janetbirdope

8 months ago

Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR19 @RheumNow abstr 2874 https://t.co/pLVAkQ7UR6

×